高危子宫内膜癌分期手术后多西他赛/顺铂化疗序贯盆腔放疗:一项2期研究
这项在韩国2个中心开展的开放标签单臂2期试验纳入62例高危子宫内膜癌患者,评估分期手术后多西他赛/顺铂化疗3周期序贯盆腔放疗的疗效与安全性。中位随访65个月,1、3、5年无进展生存率分别为98.4%、86.9%、79.1%,总生存率分别为98.4%、96.4%、96.4%。化疗后62.9%患者发生严重中性粒细胞减少,毒性总体可控。
要点
- 分期手术后多西他赛/顺铂化疗序贯盆腔放疗,5年无进展生存率79.1%、总生存率96.4%。
- 化疗后62.9%发生严重中性粒细胞减少,3.2%为3或4级贫血;放疗后16.7%为3级中性粒细胞减少。
- 作者认为高危子宫内膜癌患者可从该辅助化疗序贯放疗方案获益,毒性可控。
核心结论
- 作者认为具有高危因素的子宫内膜癌患者可从多西他赛/顺铂辅助化疗序贯放疗中获益,毒性可控。
研究设计与样本
- 开放标签、单臂2期试验,在韩国2个中心开展,纳入62例经组织学确诊并已行分期手术的子宫内膜癌患者。
- 纳入标准基于FIGO 2009分期:I期且≥2个危险因素(3级、淋巴血管间隙浸润阳性、肌层浸润超过一半);IB期和II期且为透明细胞或浆液性腺癌;II期且为1型子宫切除术后;以及III期患者。
- 治疗方案为多西他赛(70 mg/m2)联合顺铂(60 mg/m2)化疗3周期,序贯盆腔放疗45至50.4 Gy。
- 分别采用RECIST 1.1和不良事件通用术语标准4.0评估疾病状态与不良事件,研究期间按计划进行影像学检查和评估。
主要发现
- 共62例患者纳入研究,中位随访65个月(IQR,48-86个月)。
- 1年、3年、5年无进展生存率分别为98.4%、86.9%、79.1%。
- 1年、3年、5年总生存率分别为98.4%、96.4%、96.4%。
- 化疗后62.9%患者发生严重中性粒细胞减少,3.2%发生3或4级贫血;常见轻度副作用包括恶心(58.1%)和脱发(38.7%)。
- 放疗后16.7%发生3级中性粒细胞减少,少数发生1或2级贫血(3.3%),其他副作用大多轻微,未报告严重毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy after staging surgery in patients with high-risk endometrial cancer. METHODS AND MATERIALS: In this open-label, single-arm, phase 2 trial conducted at 2 South Korean centers, we enrolled patients with histologically confirmed endometrial cancer who had undergone staging surgery. Inclusion criteria were based on International Federation of Gynecology and Obstetrics (FIGO) Staging 2009: stage I patients with ≥2 risk factors (grade 3, positive lymphovascular invasion, more than half of myometrium invasion); stage IB and II patients with clear cell or serous adenocarcinoma; stage II patients post-type 1 hysterectomy; and patients at stage III. Patients underwent 3 cycles of chemotherapy with docetaxel (70 mg/m2) and cisplatin (60 mg/m2) followed by pelvic radiation therapy ranging from 45 to 50.4 Gy. Disease status and adverse events were evaluated using RECIST 1.1 and Common Terminology Criteria for Adverse Events 4.0, respectively, with scheduled imaging and assessments throughout the study. RESULTS: A total of 62 patients were included in this study and were followed for a median duration of 65 months (IQR, 48-86 months). The progression-free survival rates at 1, 3, and 5 years were 98.4%, 86.9%, and 79.1%, respectively. The overall survival rates at 1, 3, and 5 years were 98.4%, 96.4%, and 96.4%, respectively. After chemotherapy, 62.9% of patients experienced severe neutropenia, with 3.2% having grade 3 or 4 anemia. Common mild side effects included nausea (58.1%) and alopecia (38.7%). Postradiation, 16.7% experienced grade 3 neutropenia, and a few had grade 1 or 2 anemia (3.3%), with most other side effects being mild and no critical toxicities reported. CONCLUSIONS: Patients with endometrial cancer with high-risk factors could benefit from adjuvant chemotherapy using docetaxel/cisplatin, followed by radiation therapy, with manageable toxicities.
引用
- Kang OJ, Cho YJ, Lim MC, et al. Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients With High-risk Endometrial Cancer After Staging Surgery: A Phase 2 Study. Int J Radiat Oncol Biol Phys. 2024. PMID: 39557307. doi:10.1016/j.ijrobp.2024.11.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。